Increasing evidence indicates that biological therapies targeting IgE, IL-5/IL-5Rα, TSLP and IL-33/ST2 can improve not only clinical symptoms but also certain features of airway remodelling in asthma [128, 129]. This evidence concerns the gene IL5 and asthma.